Neurophysiology Module 7

Introduction

The two major inhibitory neurotransmitters released by neurons are amino acids: GABA (gamma-aminobutyric acid) and glycine. All glycine receptors are ionotropic receptors. Most GABA receptors,which belong to the GABAa receptor subtype, are also ionotropic receptors. However, a minority of GABA receptors, which belong to the GABAb receptor subtype, are metabotropic, as they activate G-proteins.

Both GABA and glycine are reuptaken from the synaptic cleft by transporters on the axon terminal.

Glycine Receptors

The binding of glycine to its receptor results in the opening of a Cl- channel. Chloride is usually in much higher concentration outside of neurons, and thus opening a Cl- channel allows Cl- to move down its concentration gradient and hyperpolarize the membrane, resulting in an IPSP. All glycine receptors are relatively simple ligand-gated ion channels. Both glycine and GABAa receptors are anchored to the postsynaptic cytoskeleton by the protein gephyrin. Downregulation of this protein can affect inhibitory neurotransmission in the nervous system, resulting in neurons that are hyperexcitable, which can lead to disease states. For example, patients with temporal lobe epilepsy have abnormally low levels of gephyrin in their temporal lobes. Glycine receptors are mainly located in the spinal cord and brainstem.

Strychnine is a fairly selective glycine receptor antagonist. There are no good selective agonists for glycine receptors other than glycine.

GABAa Receptors

GABAa receptors have many characteristics in common with glycine receptors: Binding of agonist to the receptor opens a Cl- channel, resulting in an IPSP in the postsynaptic neuron. The receptor is anchored to the membrane via gephyrin. GABAa receptors are located on the dendrites and cell bodies of neurons throughout the nervous system.

A large number of common drugs exert their actions by binding to either the main receptor site of the GABAa receptor, or bind to another part of the receptor causing a change in conformation. The latter drugs are called allosteric modulators, and fall into two classes: those that amplify the effects of agonist binding to the receptor (positive allosteric modulator) and those that reduce the effects of ligand binding to the receptor (negative allosteric modulator).

In the case of the GABAa receptor, a positive allosteric modulator results in more Cl- moving into the postsynaptic neuron when GABA binds to the receptor, and a negative allosteric modulator results in less Cl- moving into the postsynaptic neuron. In the example to the left, the positive allosteric modulator pentobarbital (a barbiturate) results in a larger IPSP when GABA binds to the GABAa receptor.

Some examples of agonists and antagonists of GABAa receptors, as well as allosteric modulators, are provided below:

• Agonist: muscimol
• Antagonist: bicuculline
• Positive allosteric modulator: benzodiazepines, barbiturates, zolpidem (ambien)
• Negative allosteric modulator: flumazenil

The effects of these drugs are as you would predict from GABA's role as the main inhibitory neurotransmitter in the nervous system. Positive allosteric modulators increase inhibition of neurons, resulting in sedation, hypnosis, and amnesia. These drugs also act as anticonvulsants. Negative allosteric modulators would have the opposite effect, and thus are not widely used in medicine. For example, flumazenil (a negative allosteric modulator of GABAa receptors) is only used to reverse the effects of benzodiazepines. The GABAa receptor antagonist bicuculline causes hyperexcitability of neurons, and thus produces seizures. This drug is provided to laboratory animals to mimic epilepsy.

GABAb Receptors

GABA also acts on G protein-coupled GABAb receptors. GABAb autoreceptors are located presynaptically at GABAergic synapses, and are also located on terminals that release glutamate. Binding of GABA to presynaptic GABAb receptors results in diminished opening of voltage-gated Ca2+ channels at the nerve terminal, and less release of neurotransmitter following an action potential.

However, most GABAb receptors are postsynaptic. Binding of GABA to the postsynaptic GABAb receptors results in increased conductance of K+, causing hyperpolarization of the postsynaptic neuron, such that it is less likely to generate an action potential.

The drug baclofen is a GABAb agonist. It is used to treat spasticity, a condition that will be discussed in this course.